Delivery system for mefenamic acid based on the nanocarrier layered double hydroxide: Physicochemical characterization and evaluation of anti-inflammatory and antinociceptive potential

Mater Sci Eng C Mater Biol Appl. 2016 Jan 1:58:629-38. doi: 10.1016/j.msec.2015.08.037. Epub 2015 Sep 1.

Abstract

Purpose: The anionic form of the drug mefenamic acid intercalated into the nanocarrier layered double hydroxide (LDH-Mef) was evaluated by anti-inflammatory and antinociceptive assays.

Methods: The LDH-Mef material was characterized by a set of physicochemical techniques, which was supported by Density Functional Theory calculations. The pharmacological effects of LDH-Mef (40 wt% of drug) were evaluated by hemolytic, anti-inflammatory activity and antinociceptive assays.

Results: In vivo assays were conducted for the first time in order to assess the LDH-Mef potential. The hemolytic effects decreased for the intercalated Mef as demonstrated by the higher tolerated hemolytic concentration (1.83 mM) compared to mefenamic acid (MefH), 0.48 mM. Pretreatment of animals with MefH or LDH-Mef reduced carrageenan-, dextran sulfate- and PGE2-induced paw edema. MefH or LDH-Mef also decrease total leucocytes and neutrophil counts of the peritoneal cavity after inflammation induction with carrageenan. In the nociception model, oral pretreatment with LDH-Mef reduced mechanical hypernociception carrageenan-induced after 3-4h and also the number of writhings induced by acetic acid.

Conclusions: This work shows the increase of the anti-inflammatory and antinociceptive potential of the drug confined into the LDH, as well as, its hemolytic effect.

Keywords: Anti-inflammatory; Antinociceptive; Density functional theory; Layered double hydroxide; Mefenamic acid.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Analgesics / chemistry*
  • Analgesics / pharmacokinetics
  • Analgesics / pharmacology
  • Analgesics / therapeutic use
  • Animals
  • Anti-Inflammatory Agents / chemistry*
  • Anti-Inflammatory Agents / pharmacokinetics
  • Anti-Inflammatory Agents / pharmacology
  • Anti-Inflammatory Agents / therapeutic use
  • Behavior, Animal / drug effects
  • Carrageenan
  • Drug Carriers / chemistry*
  • Drug Carriers / pharmacokinetics
  • Edema / chemically induced
  • Edema / drug therapy
  • Hemolysis / drug effects
  • Humans
  • Hydroxides / chemistry
  • Inflammation / chemically induced
  • Inflammation / drug therapy
  • Male
  • Mefenamic Acid / chemistry*
  • Mefenamic Acid / pharmacokinetics
  • Mefenamic Acid / pharmacology
  • Mefenamic Acid / therapeutic use
  • Mice
  • Nanoparticles / chemistry*
  • Nanoparticles / toxicity

Substances

  • Analgesics
  • Anti-Inflammatory Agents
  • Drug Carriers
  • Hydroxides
  • Mefenamic Acid
  • Carrageenan